TM9SF4 expression in tumor tissues: a novel diagnostic biomarker for gastrointestinal tumors.
Gastrointestinal neoplasms
biomarkers
diagnosis
immunohistochemistry (IHC)
Journal
Translational cancer research
ISSN: 2219-6803
Titre abrégé: Transl Cancer Res
Pays: China
ID NLM: 101585958
Informations de publication
Date de publication:
Nov 2020
Nov 2020
Historique:
received:
13
01
2020
accepted:
30
09
2020
entrez:
4
2
2022
pubmed:
1
11
2020
medline:
1
11
2020
Statut:
ppublish
Résumé
The identification of novel biomarkers for the early detection and monitoring of gastric (GC) and colorectal cancer (CRC) is of paramount importance. TM9SF4 is a newly described V-ATPase interacting protein involved in the malignant progression of cancer cells. While TM9SF4 expression pattern and cellular localization have been described in In this study, we detected by immunohistochemistry (IHC) in tumor and surrounding healthy tissues TM9SF4, in comparison with clinically adopted biomarkers CEA and CA 19-9 to evaluate TM9SF4 potential as a novel tissue marker for early detection and monitoring of GC and CRC cancers. The expression of TM9SF4, CEA and CA 19-9 was evaluated in samples from 108 cancer patients (68 with GC and 40 CRC) and in healthy tissues from 20 non-cancer patients. Our results clearly suggest that TM9SF4 expression was significantly increased in GC and CRC samples and significantly correlated to disease stage in both cancer types. We propose TM9SF4 as highly specific cancer biomarker, exploitable for disease detection and staging of gastrointestinal cancers patients, with tumor tissue levels of expression outperforming those of clinically adopted markers such as CEA and CA 19-9.
Sections du résumé
BACKGROUND
BACKGROUND
The identification of novel biomarkers for the early detection and monitoring of gastric (GC) and colorectal cancer (CRC) is of paramount importance. TM9SF4 is a newly described V-ATPase interacting protein involved in the malignant progression of cancer cells. While TM9SF4 expression pattern and cellular localization have been described in
METHODS
METHODS
In this study, we detected by immunohistochemistry (IHC) in tumor and surrounding healthy tissues TM9SF4, in comparison with clinically adopted biomarkers CEA and CA 19-9 to evaluate TM9SF4 potential as a novel tissue marker for early detection and monitoring of GC and CRC cancers.
RESULTS
RESULTS
The expression of TM9SF4, CEA and CA 19-9 was evaluated in samples from 108 cancer patients (68 with GC and 40 CRC) and in healthy tissues from 20 non-cancer patients. Our results clearly suggest that TM9SF4 expression was significantly increased in GC and CRC samples and significantly correlated to disease stage in both cancer types.
CONCLUSIONS
CONCLUSIONS
We propose TM9SF4 as highly specific cancer biomarker, exploitable for disease detection and staging of gastrointestinal cancers patients, with tumor tissue levels of expression outperforming those of clinically adopted markers such as CEA and CA 19-9.
Identifiants
pubmed: 35117275
doi: 10.21037/tcr-20-516
pii: tcr-09-11-6652
pmc: PMC8797279
doi:
Types de publication
Journal Article
Langues
eng
Pagination
6652-6659Informations de copyright
2020 Translational Cancer Research. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tcr-20-516). Dr. Guazzi reports he is an employee of HansaBioMed OU, a company that sells TM9SF4 antibodies. Dr. Chiesi and Dr. Zarovni report that they are inventors of the patent “Monoclonal antibodies, hybridomas nd methods for use”. Pubbl n. 20120122118 licensed to Exosomics spa and Dr Antonio Chiesi is an employee of HansaBioMed OU (HBM) a company that sells TM9SF4 antibodies. Dr. Lozupone reports he is one inventor of the patent “Monoclonal antibodies, hybridomas nd methods for use”. Pubbl n. 20120122118 licensed to Exosomics Spa. The other authors have nothing to disclose.
Références
Dig Surg. 2000;17(3):209-15
pubmed: 10867451
Biochim Biophys Acta. 2013 May;1832(5):606-17
pubmed: 23376112
Lancet Oncol. 2008 Mar;9(3):279-87
pubmed: 18308253
World J Gastrointest Oncol. 2015 Dec 15;7(12):422-33
pubmed: 26690833
Cell Death Differ. 2018 Feb;25(2):368-379
pubmed: 29125601
Int J Clin Oncol. 2015 Aug;20(4):725-35
pubmed: 25652905
Genes Chromosomes Cancer. 2010 Nov;49(11):998-1013
pubmed: 20645416
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
PLoS One. 2015 May 11;10(5):e0126968
pubmed: 25961573
World J Gastroenterol. 2014 Oct 14;20(38):13842-62
pubmed: 25320521
J Clin Oncol. 2006 Nov 20;24(33):5313-27
pubmed: 17060676
Oncogene. 2015 Oct 1;34(40):5163-74
pubmed: 25659576
Oncotarget. 2017 Jun 27;8(37):61935-61943
pubmed: 28977916
Gut. 2015 Sep;64(9):1485-94
pubmed: 25994221
J Gastrointest Oncol. 2012 Sep;3(3):262-84
pubmed: 22943017
Best Pract Res Clin Gastroenterol. 2014 Dec;28(6):1093-106
pubmed: 25439074
Ann Surg Oncol. 2010 Jun;17(6):1471-4
pubmed: 20180029
Trends Biochem Sci. 2015 Oct;40(10):611-622
pubmed: 26410601
EMBO Rep. 2009 Dec;10(12):1348-54
pubmed: 19893578
Case Rep Gastroenterol. 2017 Sep 26;11(3):545-553
pubmed: 29033776
Int J Cancer. 2014 Jun 1;134(11):2513-22
pubmed: 23852704
Int J Oncol. 2014 Oct;45(4):1345-54
pubmed: 25070157
Am J Surg Pathol. 1996 Oct;20(10):1161-81
pubmed: 8827022
J Innate Immun. 2015;7(1):37-46
pubmed: 25139117
Ir J Med Sci. 1999 Apr-Jun;168(2):124-6
pubmed: 10422394